Luoxin Pharmaceuticals Group Stock Co., Ltd. (SHE:002793)
China · Delayed Price · Currency is CNY 5.39
-0.12 (-2.18%)
Apr 29, 2026, 3:04 PM CST
SHE:002793 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Revenue | 2,314 | 2,214 | 2,615 | 2,329 | 3,470 | 6,370 |
Other Revenue | 59.09 | 59.09 | 32.7 | 35.27 | 117.61 | 108.29 |
| 2,373 | 2,273 | 2,647 | 2,364 | 3,588 | 6,478 | |
Revenue Growth (YoY) | -2.78% | -14.12% | 11.99% | -34.11% | -44.62% | 6.26% |
Cost of Revenue | 1,149 | 1,182 | 1,607 | 1,340 | 2,694 | 3,232 |
Gross Profit | 1,224 | 1,092 | 1,040 | 1,024 | 893.98 | 3,246 |
Selling, General & Admin | 1,272 | 1,189 | 1,418 | 1,338 | 2,229 | 2,234 |
Research & Development | 92.66 | 91.6 | 87.41 | 112.27 | 204.73 | 320.95 |
Other Operating Expenses | 23.59 | 17.08 | -2.01 | -1.2 | 40.17 | 74.48 |
Operating Expenses | 1,341 | 1,250 | 1,517 | 1,504 | 2,494 | 2,726 |
Operating Income | -116.91 | -158.6 | -476.89 | -479.63 | -1,600 | 519.59 |
Interest Expense | -55.59 | -55.59 | -64.38 | -75.97 | -122.67 | -105.18 |
Interest & Investment Income | 18.34 | 2.55 | 6.3 | 24.84 | 176.24 | 9.87 |
Currency Exchange Gain (Loss) | -0.49 | -0.49 | 2.09 | 4.19 | -8.88 | 0.64 |
Other Non Operating Income (Expenses) | -35.4 | -4.25 | -1.31 | -0.87 | -2.06 | 5.2 |
EBT Excluding Unusual Items | -186.64 | -216.38 | -534.19 | -527.45 | -1,557 | 430.11 |
Gain (Loss) on Sale of Investments | -84.41 | -84.41 | -216.58 | -4.05 | 2.01 | -3.26 |
Gain (Loss) on Sale of Assets | 3.3 | 3.08 | 0.24 | -12.18 | 1.74 | -3.31 |
Asset Writedown | -34.57 | -31.34 | -229.97 | -56.64 | -7.85 | -0.72 |
Other Unusual Items | 38.17 | 38.17 | 27.65 | -3.8 | 98.25 | 62.38 |
Pretax Income | -264.15 | -290.87 | -952.85 | -604.11 | -1,463 | 485.2 |
Income Tax Expense | -6.48 | -6.35 | 99.4 | 164.81 | -205.64 | 63.55 |
Earnings From Continuing Operations | -257.68 | -284.53 | -1,052 | -768.92 | -1,257 | 421.65 |
Minority Interest in Earnings | -12.4 | -4.05 | 86.76 | 107.78 | 32.37 | -15.55 |
Net Income | -270.08 | -288.58 | -965.5 | -661.14 | -1,225 | 406.1 |
Net Income to Common | -270.08 | -288.58 | -965.5 | -661.14 | -1,225 | 406.1 |
Net Income Growth | - | - | - | - | - | 26.63% |
Shares Outstanding (Basic) | 1,062 | 1,062 | 1,066 | 1,084 | 1,424 | 1,450 |
Shares Outstanding (Diluted) | 1,062 | 1,062 | 1,066 | 1,084 | 1,424 | 1,450 |
Shares Change (YoY) | 3.44% | -0.39% | -1.65% | -23.91% | -1.79% | -0.51% |
EPS (Basic) | -0.25 | -0.27 | -0.91 | -0.61 | -0.86 | 0.28 |
EPS (Diluted) | -0.25 | -0.27 | -0.91 | -0.61 | -0.86 | 0.28 |
EPS Growth | - | - | - | - | - | 27.27% |
Free Cash Flow | 207.5 | 220.88 | -273.2 | 224.5 | -1,134 | -188.4 |
Free Cash Flow Per Share | 0.20 | 0.21 | -0.26 | 0.21 | -0.80 | -0.13 |
Dividend Per Share | - | - | - | - | - | 0.030 |
Dividend Growth | - | - | - | - | - | -40.00% |
Gross Margin | 51.58% | 48.02% | 39.30% | 43.33% | 24.92% | 50.10% |
Operating Margin | -4.93% | -6.98% | -18.01% | -20.29% | -44.59% | 8.02% |
Profit Margin | -11.38% | -12.69% | -36.47% | -27.97% | -34.14% | 6.27% |
Free Cash Flow Margin | 8.74% | 9.72% | -10.32% | 9.50% | -31.61% | -2.91% |
EBITDA | 79.4 | 36.99 | -284.12 | -288.45 | -1,394 | 705.83 |
EBITDA Margin | 3.35% | 1.63% | -10.73% | -12.20% | -38.87% | 10.90% |
D&A For EBITDA | 196.3 | 195.6 | 192.77 | 191.18 | 205.33 | 186.24 |
EBIT | -116.91 | -158.6 | -476.89 | -479.63 | -1,600 | 519.59 |
EBIT Margin | -4.93% | -6.98% | -18.01% | -20.29% | -44.59% | 8.02% |
Effective Tax Rate | - | - | - | - | - | 13.10% |
Revenue as Reported | 2,273 | 2,273 | 2,647 | 2,364 | 3,588 | 6,478 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.